Delisting Determination, The Nasdaq Stock Market, LLC, May 11, 2026
Iterum Therapeutics plc
The Nasdaq Stock Market LLC (the Exchange) has determined to remove 
from listing the ordinary shares of Iterum Therapeutics plc 
effective at the opening of the trading session on July 6, 2026. 
Based on review of information provided by the Company, Nasdaq Staff 
determined that the Company no longer qualified for listing on the 
Exchange pursuant to Listing Rule 5550(a)(2).
The Company was notified of the Staff determination on February 24, 2026. 
On March 3, 2026 the Company exercised its right to appeal 
the Staff determination to the Listing Qualifications Hearings 
Panel (Panel) pursuant to Listing Rule 5815. 
On March 27, 2026, the Company withdrew its appeal of
Nasdaq Staff's Delist Determination Letter. 
On March 30, 2026 Nasdaq issued a letter informing the Company
that its ordinary shares would be suspended from the Exchange.
The Company ordinary shares were suspended on April 1, 2026. The 
Staff determination to delist the Company ordinary shares 
became final on April 1, 2026.